<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00181168</url>
  </required_header>
  <id_info>
    <org_study_id>THYR01105ORP</org_study_id>
    <secondary_id>JHM IRB #1</secondary_id>
    <nct_id>NCT00181168</nct_id>
  </id_info>
  <brief_title>Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer</brief_title>
  <official_title>Utility of Recombinant Human Thyrotropin (rTSH) PET-CT Fusion Scanning to Identify Residual Well-Differentiated Epithelial Thyroid Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine [for patients with previously treated
      well-differentiated thyroid cancer and evidence of residual disease based on serum
      thyroglobulin (Tg) level] whether positron emission tomography-computed tomography (PET-CT)
      fusion scanning performed after recombinant TSH (rTSH, thyrotropin alfa for injection) will
      be more sensitive for the detection of disease sites than PET-CT scanning without rTSH. The
      study will also determine if this information will significantly alter the therapeutic
      approach in some patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2005</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PET-CT fusion scanning after rTSH will be more sensitive to detect disease sites than scanning without rTSH; this information will significantly alter the therapeutic approach in some patients.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Increase in FDG PET SUV after rTSH will be more specific for metastases than for nonneoplastic processes (e.g., infection and muscle contraction).</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Thyroid Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant thyrotropin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (aged ≥ 18 years) with history of treated well-differentiated epithelial
             thyroid carcinoma (papillary, follicular or Hurthle cell), for which total or near
             total thyroidectomy plus postoperative radioiodine remnant ablation with 131-I has
             either been performed or found to be unnecessary by radioiodine imaging after TSH
             stimulation.

          -  Serum thyroglobulin (Tg) concentration ≥ 10 ng/mL (in the absence of interfering Tg
             autoantibodies).

          -  No findings of a &quot;qualifying&quot; radioiodine whole body scan that are sufficient to
             localize the disease suspected on the basis of the serum Tg.

          -  Inconclusive disease localization despite clinical assessment, cervical sonography, CT
             or magnetic resonance (MR) of the chest, and when appropriate other imaging and biopsy
             procedures. Patients must have no more than three foci of known or suspected
             extra-cervical metastasis.

          -  Must be in stable medical condition.

          -  Must be able to fully understand the protocol and be compliant with instructions.

        Exclusion Criteria:

          -  Diabetes mellitus, due to interference with fluorodeoxyglucose (FDG) PET scanning.

          -  Claustrophobia, inability to lay supine, or other factors preventing cooperation with
             scanning procedures.

          -  Withdrawal of thyroid hormone or rTSH administration within the preceding month.

          -  Presence of circulating Tg autoantibodies interfering with serum Tg measurement.

          -  Women who are pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul W Ladenson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul W Ladenson, MD</last_name>
    <phone>410-955-3663</phone>
    <email>ladenson@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marge E Ewertz, RN</last_name>
    <phone>410-955-1667</phone>
    <email>meewertz@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Johns Hopkins Division of Endocrinology &amp; Metabolism</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul W Ladenson, MD</last_name>
      <phone>410-955-3663</phone>
      <email>ladenson@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Marge E Ewertz, RN</last_name>
      <phone>410-955-1667</phone>
      <email>meewertz@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Paul W Ladenson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven I Sherman, MD</last_name>
      <email>sisherma@mail.mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Steven I Sherman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute Gustave Roussy</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Schlumberger, MD</last_name>
      <email>schlumbg@igr.fr</email>
    </contact>
    <investigator>
      <last_name>Martin Schlumberger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie Leboulleux, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chin BB, Patel P, Cohade C, Ewertz M, Wahl R, Ladenson P. Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2004 Jan;89(1):91-5.</citation>
    <PMID>14715833</PMID>
  </reference>
  <verification_date>September 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>September 24, 2007</last_update_submitted>
  <last_update_submitted_qc>September 24, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2007</last_update_posted>
  <keyword>thyroid cancer</keyword>
  <keyword>PET scan</keyword>
  <keyword>recombinant thyrotropin</keyword>
  <keyword>thyroglobulin</keyword>
  <keyword>Thyroid cancer, differentiated epithelial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcitonin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 21, 2015</submitted>
    <returned>May 6, 2015</returned>
    <submitted>May 7, 2015</submitted>
    <returned>May 22, 2015</returned>
    <submitted>December 11, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

